Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Capital Expenditures (2018 - 2025)

TELA Bio has reported Capital Expenditures over the past 8 years, most recently at $91000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $91000.0 for Q4 2025, down 65.53% from a year ago — trailing twelve months through Dec 2025 was $448000.0 (down 54.7% YoY), and the annual figure for FY2025 was $448000.0, down 54.7%.
  • Capital Expenditures for Q4 2025 was $91000.0 at TELA Bio, down from $211000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for TELA hit a ceiling of $304000.0 in Q1 2024 and a floor of -$172000.0 in Q4 2021.
  • Median Capital Expenditures over the past 5 years was $118500.0 (2023), compared with a mean of $111050.0.
  • Biggest five-year swings in Capital Expenditures: tumbled 552.63% in 2021 and later surged 20600.0% in 2023.
  • TELA Bio's Capital Expenditures stood at -$172000.0 in 2021, then surged by 99.42% to -$1000.0 in 2022, then surged by 20600.0% to $205000.0 in 2023, then rose by 28.78% to $264000.0 in 2024, then tumbled by 65.53% to $91000.0 in 2025.
  • The last three reported values for Capital Expenditures were $91000.0 (Q4 2025), $211000.0 (Q3 2025), and $114000.0 (Q2 2025) per Business Quant data.